Literature DB >> 3652038

Effects of pharmacological concentrations of estrogens on proliferation and cell cycle kinetics of human breast cancer cell lines in vitro.

R R Reddel1, R L Sutherland.   

Abstract

High dose estrogen therapy has been used effectively in the treatment of human breast cancer. To understand the mechanisms involved, the effects of high concentrations (5-100 microM) of estrogens were studied in estrogen receptor (ER) positive (T-47D and MCF-7) and ER negative (MDA-MB-330) human breast cancer cell lines in vitro. Inhibition of cellular proliferation was seen with the synthetic estrogen diethylstilbestrol (DES) at concentrations greater than 10 microM in each of the three cell lines. In T-47D cells DES was shown by clonogenic survival assays to be cytotoxic. This effect was evident in both plateau phase and exponentially growing cultures, in contrast to the effects of the antiestrogen tamoxifen, which has minimal effects on plateau phase cells. The effects of DES on the proliferation of exponentially growing cultures were accompanied by changes in cell cycle parameters which included an increase in the percentages of S-phase, G2 + M, and polyploid cells and a corresponding decrease in the percentage of G0-G1 cells. These changes, which contrasted with the known effects of tamoxifen, were not seen in the non- or slowly cycling plateau phase T-47D cells. Such results are consistent with two mechanisms of action of high dose estrogen in vitro: a cell cycle phase-specific effect and cell cycle-independent cytotoxicity. The stereoisomers 17 alpha-estradiol and 17 beta-estradiol had similar potency to DES in inhibiting cell proliferation and inducing these changes in cell cycle parameters in both MCF-7 and MDA-MB-330 cells. The high-dose estrogen effect was ligand specific in that estrone and estriol were less potent than DES, 17 alpha-estradiol and 17 beta-estradiol in inhibiting cell proliferation, and the characteristic cell cycle changes were produced only by concentrations of estriol greater than 75 microM and not at all by estrone at concentrations up to 100 microM. The androgens testosterone and dihydrotestosterone were similar in effect to estrone. The cell cycle changes associated with estrogen-induced growth inhibition in vitro are identical to those observed during regression of ER positive but not ER negative human tumor xenografts in nude mice. However, the role of ER in mediating estrogen-induced regression of ER positive tumors in vivo remains undefined.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3652038

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity.

Authors:  G Bernhardt; H Reile; H Birnböck; T Spruss; H Schönenberger
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Diethylstilbestrol induces arrest of rat vascular smooth muscle cell cycle progression through downregulation of cyclin D1 and cyclin E.

Authors:  Min-Cheol Song; Junsoo Park; Tack-Joong Kim
Journal:  Mol Cell Biochem       Date:  2011-09-10       Impact factor: 3.396

3.  In vitro sensitivity testing of human breast cancer cells to hormones and chemotherapeutic agents.

Authors:  J T Emerman; A W Tolcher; P M Rebbeck
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.

Authors:  Payel Chatterjee; Michael T Schweizer; Jared M Lucas; Ilsa Coleman; Michael D Nyquist; Sander B Frank; Robin Tharakan; Elahe Mostaghel; Jun Luo; Colin C Pritchard; Hung-Ming Lam; Eva Corey; Emmanuel S Antonarakis; Samuel R Denmeade; Peter S Nelson
Journal:  J Clin Invest       Date:  2019-07-16       Impact factor: 14.808

5.  17alpha-estradiol inhibits LAPC-4 prostatic tumor cell proliferation in cell cultures and tumor growth in xenograft animals.

Authors:  Yaming Qiao; Zhi-Kai Zhang; Li-Qun Cai; Chen Tan; Julianne L Imperato-McGinley; Yuan-Shan Zhu
Journal:  Prostate       Date:  2007-12-01       Impact factor: 4.104

6.  Discovery of novel splice forms and functional analysis of cancer-specific alternative splicing in human expressed sequences.

Authors:  Qiang Xu; Christopher Lee
Journal:  Nucleic Acids Res       Date:  2003-10-01       Impact factor: 16.971

7.  Proliferative inhibition of human breast carcinoma cells by high concentration estradiol does not alter radiosensitivity.

Authors:  D E Wazer; M Joyce; G Solares; R Schmidt-Ullrich
Journal:  Breast Cancer Res Treat       Date:  1991-08       Impact factor: 4.872

8.  The combined influence of multiple sex and growth hormones on risk of postmenopausal breast cancer: a nested case-control study.

Authors:  Shelley S Tworoger; Bernard A Rosner; Walter C Willett; Susan E Hankinson
Journal:  Breast Cancer Res       Date:  2011-10-21       Impact factor: 6.466

9.  During development, 17alpha-estradiol is a potent estrogen and carcinogen.

Authors:  R A Hajek; A D Robertson; D A Johnston; N T Van; R K Tcholakian; L A Wagner; C J Conti; M L Meistrich; N Contreras; C L Edwards; L A Jones
Journal:  Environ Health Perspect       Date:  1997-04       Impact factor: 9.031

10.  The E-screen assay: a comparison of different MCF7 cell stocks.

Authors:  M Villalobos; N Olea; J A Brotons; M F Olea-Serrano; J M Ruiz de Almodovar; V Pedraza
Journal:  Environ Health Perspect       Date:  1995-09       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.